toremifene and Soft-Tissue-Neoplasms

The EORTC Melanoma Cooperative Group conducted a phase II trial (study number 18891) to study the effect of Toremifene in 45 patients with advanced, metastatic melanoma. Male and female patients, median age 61 (range 23-88) years received a mean total dose of 11 g (4.3-62.6) orally for at least 6 weeks. No objective remissions were seen. Four patients (3 women and 1 man; 9%) experienced 3-6 months' disease stabilization. The toxicity of the drug, given at a dose of 240 mg daily, was negligible. Because of the minimal side-effects, Toremifene may be recommended for patients who have only a small number of slowly growing metastases, in particular to soft tissue and lung.

Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Menopause; Middle Aged; Sex Factors; Skin Neoplasms; Soft Tissue Neoplasms; Toremifene